Arsb Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| ARSB Gene |
|---|
| Gene Symbol | ARSB |
| Full Name | Arylsulfatase B |
| Chromosomal Location | 5q14.1 |
| NCBI Gene ID | 409 |
| OMIM | 253200 |
| Ensembl ID | ENSG00000113273 |
| UniProt ID | P15884 |
| Associated Diseases | Mucopolysaccharidosis Type VI (MPS VI), Neurodegeneration |
The ARSB gene (Arylsulfatase B) encodes a lysosomal hydrolase enzyme that catalyzes the removal of sulfate groups from glycosaminoglycans (GAGs), particularly dermatan sulfate and chondroitin sulfate. This gene is essential for the degradation of these complex carbohydrates within lysosomes.
Arylsulfatase B is a member of the sulfatase family of enzymes. The enzyme hydrolyzes the sulfate ester bond at the non-reducing end of dermatan sulfate and chondroitin sulfate, playing a critical role in the lysosomal degradation pathway for glycosaminoglycans.
- Catalyzes hydrolysis of sulfate groups from GAGs
- Requires a unique post-translational modification (formylglycine cofactor)
- Optimal activity in acidic lysosomal environment (pH 5.0-5.5)
- Homodimeric structure with each subunit approximately 56 kDa
- Lysosomal Function: Essential for normal catabolism of dermatan sulfate and chondroitin sulfate
- Proteoglycan Turnover: Regulates the degradation and recycling of proteoglycans in the extracellular matrix
- Cell Signaling: Proper GAG metabolism influences cell growth, migration, and signaling
Also known as Maroteaux-Lamy syndrome, MPS VI is caused by autosomal recessive mutations in the ARSB gene, resulting in deficient or absent arylsulfatase B activity.
Clinical Features:
- Coarse facial features
- Short stature
- Joint stiffness and contractures
- Dysostosis multiplex
- Corneal clouding
- Hearing loss
- Valvular heart disease
- Neurological involvement in some patients
Inheritance Pattern: Autosomal recessive
While MPS VI is primarily a systemic disorder, neurological manifestations can include:
- Delayed neurodevelopment in severe cases
- Hydrocephalus
- Spinal cord compression from atlantoaxial subluxation
- Carpal tunnel syndrome affecting hand function
- ARSB is expressed in various tissues including brain
- Higher expression in liver and skeletal muscle
- Lysosomal enzymes generally expressed in neurons and glia
- Expression pattern consistent with role in cellular waste removal
Expression data from the Allen Brain Atlas indicates moderate expression across multiple brain regions, with particular enrichment in cells with high lysosomal activity.
- Galsulfase (Naglazyme®) is an FDA-approved recombinant human arylsulfatase B
- Approved for treatment of MPS VI
- Does not cross the blood-brain barrier, limiting CNS effects
- AAV-mediated gene delivery being explored
- Potential for treating neurological manifestations
- Litjens T, et al. (1996). "Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS VI patients." Am J Hum Hum Genet. PMID:8659546
- Karageorgos L, et al. (2007). "Mutational analysis of 11 patients with mucopolysaccharidosis type VI." Clin Genet. PMID:17250665
- Harmatz P, et al. (2018). "Long-term outcomes in mucopolysaccharidosis type VI: 10-year results of the RhGUS enzyme replacement therapy trial." Mol Genet Metab. PMID:29428225
The study of Arsb Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.